NCT01946074: Study of ABT-165 in Subjects With Advanced Solid Tumors

NCT01946074
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Chemotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 99 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with uncontrolled metastases to the central nervous system (CNS)
https://ClinicalTrials.gov/show/NCT01946074

Comments are closed.

Up ↑